群馬大学 大学院保健学研究科 医学部保健学科

本文ヘジャンプします"
  • キャンパスマップ
  • サイトマップ
  • お問い合わせ
  • アクセスマップ
  • 日本語
  • English

保健学科について / 保健学研究科について

プロフィール 教育と研究 臨床業務、地域・国際貢献 業 績

▌プロフィール

齋藤 貴之
さいとうたかゆき 齋藤 貴之 Saitoh Takayuki 応用保健学ユニット 生体情報検査学領域 E-mail website

現 職
群馬大学大学院保健学研究科生体情報検査科学講座 教授 (主任)

資 格
日本血液学会専門医、日本血液学会指導医、日本血液学会評議員、日本検査血液学会評議員、日本骨髄腫学会代議員、日本内科学認定医、造血細胞移植認定医

所属学会
日本内科学会、日本血液学会、日本臨床血液学会、日本造血細胞移植学会、日本検査血液学会、日本骨髄腫学会

コメント

多発性骨髄腫を中心に血液疾患の病態解明やDNA修復の研究を行っています。群馬大学血液内科、輸血部、腫瘍センター、生体調節研究所と共同研究をしています。

▌教育と研究

研究内容

Research:病気のなりやすさは人によって違いがありますが、その違いを遺伝子多型によって探索しています。DNAは、外的刺激(放射線、タバコなどの酸化ストレス等)や内的環境(ミトコンドリアの電子伝達系などにより生じた活性酸素種等)により、恒常的に損傷を受けています。DNAの修復機構の異常は、がん化の原因になったり、治療効果にも影響を与えます。私たちは、血液疾患におけるDNA修復の役割について注目しています。また、がんはまわりの免疫機構を変化させ、自ら生き延びる戦略をとっています。その免疫機構を研究し、治療に役に立つ研究をしたいと考えています。

 

1. Polymorphisms :
遺伝子多型研究:特発性血小板減少性紫斑病、多発性骨髄腫、白血病、骨髄異形成症候群など血液疾患の病気のなりやすさや重症度を調べています。

 

2.DNA repair:
DNA修復の研究: 遺伝子多型から得られた所見をもとに、DNA修復とがん化や治療効果の関係について調べています。

 

3.Multiple myeloma:
多発性骨髄腫における病態の解明や患者さんに役立てる治療法の開発を目指して研究しています。

 

4.Cancer immunity:
がんの免疫機構の研究をしています。

教育業務

学部教育:

「学生さんが血液学・免疫学がこんなに面白いんだと思ってもらえるような講義・実習をします。」
「困っている人がいたら、さっと手をさしのべることができる保健人になっていただきたいです。」

検査技術科学専攻では、基礎医学I、生体防御学、生体防御学実習、血液検査学、血液検査学実習を担当しています。また、各専攻をこえて行われるチームワーク実習にも参加しています。

 

大学院教育:

「保健学は大学院の時代です。群馬大学以外の卒業生、社会人大学院生、外国人留学生も歓迎です。大学院生は国内・国際学会で発表しています。」これからの時代はこの3つが大切。学(専門性)を身に付けよ、英語を勉強せよ、AIを使え!です。一緒に学びましょう!
組織・細胞情報科学特別研究Ⅱ、応用保健学セミナーを担当しています。

▌臨床業務、地域・国際貢献

臨床業務

群馬大学医学部附属病院外来で血液疾患の診療やカンファレンスに参加しています。骨髄移植の調整医師をしています。群馬県血液疾患研究会やがんプロフェッショナル養成プランに協力しています。

地域・国際貢献

国際交流、GFL、医学部EnglishCafeの運営に関わっています。保健分野のグローバルを推進します。

GFL:https://gfl.jimu.gunma-u.ac.jp/
EnglishCafe:https://www.instagram.com/englishshowa/
      https://sites.google.com/a/gunma-u.ac.jp/english-cafe-showa/
国際保健推進室、ワシントン大学交換留学、保健学科GFLの責任者をしています。WHO協力センターの多職種連携教育に参加しています。語学留学、専攻の留学など留学の興味がある方はお尋ねください!

・多様性の推進
国籍、人種、宗教、性、職種、年齢を超えたダイバーシティを推進します。群馬大学は2019年3月に「性の多様性に関する基本的考え」「性の多様性に関する対応ガイドライン」http://www.gunma-u.ac.jp/information/51833を策定しました。相談員がメールで対応します(niji★gunmau.ac.jp  <★ → @>)。

▌業 績

(和文:著書・その他)

  1. 大崎洋平, 小川孔幸, 森田晶人, 日下田大輔, 清水啓明, 柳沢邦雄, 石埼卓馬, 齋藤貴之, 塚本憲史, 亀田高志, 半田寛 治療抵抗性妊娠合併特発性血小板減少性紫斑病の2例 The Kitakanto Medical Journal 69:227-232 2019.
  2. 下田 佳央莉, Bulganchimeg Sanjmyatav, 村野万伊加, 坂本雅昭, 外里冨佐江, 森淑江, Gaalan Khulan, 菊地千一郎, 土屋謙仕, 野口直人, 越智貴子, 齋藤貴之 Skypeを活用して開催した国際シンポジウムの評価 モンゴル国のリハビリテーションの発展を目指して The Kitakanto Medical Journal 69:195-203, 2019.
  3. 齋藤貴之, 岸美紀子, 鯉淵典之, 小山洋, 坂本雅昭, 石崎 泰樹 群馬大学医学部における学生国際交流 北関東医学 69:263-265, 2019.
  4. 梨木恵実子, 内田陽子, 齋藤貴之 群馬県の訪問看護ステーションにおけるCOPDアクションプランに関する調査 The Kitakanto Medical Journal 69, 7-15, 2019.
  5. 島内陽子, 馬郡幹也, 鈴木康太, 細貝真弓, 戸所大輔, 齋藤貴之, 秋山英雄 白血病細胞の眼内浸潤を認めた成人T細胞白血病の1例 臨床眼科 72:1235-1239, 2018.
  6. 牧野孝俊, 金泉志保美, 篠崎博光, 齋藤貴之, 安部由美子, 山路雄彦, 佐藤江奈, 川島智幸, 岸美紀子, 小松康宏, 田中和美 【進化するIPE 地域包括ケアシステムが求める多職種連携教育の今】(Part3-1)導入事例 大学の特色を生かしたIPE 全人的医療とチーム医療に貢献できる人材の育成を目指して 群馬大学の多職種連携教育 看護展望 43:0842-0848, 2018.
  7. 石埼卓馬、横濱章彦、清水啓明、栁澤邦雄、小川孔幸、三井健揮、小磯博美、滝沢牧子、齋藤貴之、村上博和、塚本典史、半田寛Etoposide 中等量療法による末梢血幹細胞採取 The Kitakanto Medical Journal 63:43-47, 2018
  8. 外里冨佐江, 篠崎博光, 金泉志保美, 牧野孝俊, 齋藤貴之, 安部由美子, 吉田朋美, 松井弘樹, 時田佳治, 山路雄彦, 佐藤江奈, 李範爽, 川島智幸, 鎌田英男, 岸美紀子, 蒲章則, 渡邊秀臣【地域・在宅の拡がるIPEの新たな取り組み】群馬大学のInterprofessional education(IPE)の取り組み 保健医療福祉連携 10:119-127, 2017.
  9. 村上博和, 笠松哲光, 齋藤貴之, 半田寛【慢性疾患となった骨髄腫-どのように診断するか? どのように付き合っていくか?】骨髄腫治療薬の温故知新 アルキル化薬とステロイド 内科 120:865-869, 2017.
  10. 笠松哲光, 齋藤貴之, 村上博和 多発性骨髄腫治療における免疫チェックポイント分子の意義 BIO Clinica 32:917-921, 2017.
  11. 齋藤貴之 DNA修復に着眼した多発性骨髄腫の耐性機構の解明 BIO Clinica 32:908-911, 2017.
  12. 笠松哲光, 齋藤貴之, 村上博和 疾患と検査値の推移 多発性骨髄腫 検査と技術 45:758-763, 2017.
  13. 齋藤貴之、村上博和.カルフィルゾミブ登場の意義と期待.多発性骨髄腫診療PROGRESS. 赤司浩一監修.メディカルビュー社,2016年11月1日,pp80-85.
  14. 齋藤貴之、笠松哲光、村上博和.多発性骨髄腫診断基準と病期分類の変遷と展望.多発性骨髄腫学―最新の臨床と基礎研究―、日本臨床 2016:74(Supple5): 15-20.
  15. 半田寛、齋藤貴之、村上博和.多発性骨髄腫におけるmiRNA異常.造血器腫瘍アトラス改訂第5版.谷脇雅史、横田昇平、黒田純也編、日本医事新報社.2016年8月15日.pp376-383
  16. 半田寛、齋藤貴之、村上博和  多発性骨髄腫におけるエピゲノム異常とmiRNA 血液内科 72巻第5号 684-690 2016
  17. 半田寛、齋藤貴之、村上博和 高齢者骨髄腫の治療-脆弱性の評価と治療の選択・用量調節 日本臨床74巻増刊号5 多発性骨髄腫学 2016
  18. 村上博和、齋藤貴之、笠松哲光.血液・リンパ系腫瘍 再発・難治性造血器腫瘍の治療―新規・追加承認薬とその位置づけ―Ⅲ.多発性骨髄腫. がんと化学療法 2016; 43(5): 539-544.
  19. 笠松哲光、齋藤貴之、村上博和.病気の話し 多発性骨髄腫.検査と技術.2015;43(5):372-378.
  20. 齋藤貴之、村上博和 骨髄腫の診断と鑑別診断 PharmaMedica33巻P.53-56 2015年12月
  21. 半田寛、齋藤貴之、村上博和 骨髄腫におけるマイクロRNAとエピゲノムネットワーク 血液内科 70(6) 674-682, 2015
  22. 半田寛、齋藤貴之、村上博和レナリドミドの免疫調整作用 (特集 多発性骨髄腫の病態と最新治療 : 基礎と臨床の最新情報) — (特論) 日本臨床 73(1), 156-161, 2015-01
  23. 長坂 伊左男, 三井 健揮, 石埼 卓馬, 小磯 博美, 横濱 章彦, 齋藤貴之, 平戸 純子, 五十嵐 忠彦, 小島 勝, 塚本 憲史,野島 美久, 村上 博和, 半田 寛 寛解16年後に再発した精巣原発びまん性大細胞型B細胞リンパ腫 臨床血液 Vol. 56 (2015) No. 1
  24. 村上博和、齋藤貴之、笠松哲光 多発性骨髄腫および類縁疾患.日本検査血液学会編 スタンダード検査血液学第3版.日本検査血液学会編、医歯薬出版 2014年9月
  25. 齋藤貴之、笠松哲光、村上博和 多発性骨髄腫Updating 第6巻V.形質細胞腫瘍~特異な病型~ 1.骨の孤発性形質細胞腫 医薬ジャーナル社 P.226-232 2014年8月
  26. 齋藤貴之、村上博和 白血病と言われたら.発行 特定非営利活動法人 全国骨髄バンク推進連絡協議会疾患・治療編.多発性骨髄腫 P.83-95 2014.
  27. 齋藤貴之、村上博和、半田寛 多発性骨髄腫 Updating 第5巻 移植非適応骨髄腫の治療 高齢者治療の問題点 医薬ジャーナル社 P.104-111 2014年3月
  28. 齋藤貴之、村上博和、半田寛 多発性骨髄腫 Updating 第5巻 移植非適応骨髄腫の治療 日本人におけるメルファランの至適投与量 医薬ジャーナル社 P.54-59 2014年3月
  29. 村上博和、齋藤貴之、半田寛 多発性骨髄腫に対するプロテアソーム阻害薬治療癌と化学療法 40巻 P.583-588 2013年 5月
  30. 村上博和、齋藤貴之、半田寛 血液症候群(第2版)-その他の血液疾患を含めて‐ Ⅲ Ⅹ血漿タンパクの異常 クリオグロブリン血症 日本臨床社 P.657-665 2013年5月
  31. 齋藤貴之、村上博和 多発性骨髄腫 Updating 第2巻 多発性骨髄腫の症候/合併症とのその対策 多発性骨髄腫に多く見られる感染症 医薬ジャーナル社 P.206-215 2013年3月
  32. 村上博和、齋藤貴之、半田寛 EBM 血液疾患の治療 2013-2014 移植非適応高齢者骨髄腫治療指針 中外医学社 P.376-380 2012年10月
  33. 村上博和、半田寛、齋藤貴之 骨髄腫を疑う所見から専門医までの検査の進め方 Medical Practice 29巻 2012年5月
  34. 斉藤貴之、塚本憲史 多発性骨髄腫治療マニュアル 原発性アミロイドーシス P.287-292、2012年 4月
  35. Murakami H, Yokohama A, Saitoh T, Tsukamoto N, Handa H Diagnosis and prognostic factors in patients with multiple myeloma 日本臨床 70巻 P.284-288 2012年 4月
  36. 村上博和、斉藤貴之.白血病リンパ腫骨髄腫 今日の診断と治療第4版木崎昌弘編、中外医学社P.314-323 2011年10月
  37. 斉藤貴之、塚本憲史、村上博和 多発性骨髄腫の病期分類と予後予測 「内科」南江堂 第108巻第2号 P.221-226 2011年8月
  38. 斉藤貴之 、塚本憲史、村上博和 高齢者多発性骨髄腫に対する治療 「血液内科」科学評論社第62巻第3号P.314-323 2011年3月
  39. 村上博和、半田寛、斉藤貴之 IMiDsの基礎と臨床 第Ⅱ章 臨床の実際 1.多発性骨髄腫とiMiDs 2)再発・難治例におけるiMiDs医薬ジャーナルP.47-59 2010年8月
  40. 村上博和、半田寛、斉藤貴之多発性骨髄腫の最近の治療総合臨床 第59巻第8号P.1835-P.1837 2010年8月
  41. 村上博和、半田寛、齋藤貴之. がん診療update多発性骨髄腫. 日本医師会雑誌第138巻特別号(1)P.300-302 2010年6月
  42. 村上博和、半田寛、斉藤貴之、小河原はつ江多発性骨髄腫 多様な病期分類 カレントテラピー第28巻第3号 P.32-36 2010年3月

(英語論文)

  1. Kobayashi N, Oda T, Takizawa M, Ishizaki T, Tsukamoto N, Yokohama A, Takei H, Saitoh T, Shimizu H, Honma K, Kimura-Masuda K, Kuroda Y, Ishihara R, Murakami Y, Murakami H, Handa H. Integrin α7 and Extracellular Matrix Laminin 211 Interaction Promotes Proliferation of Acute Myeloid Leukemia Cells and Is Associated with Granulocytic Sarcoma. Cancers (Basel). 2020 Feb 5;12(2).
  2. Gotoh N, Minato Y, Saitoh T, Takahashi N, Kasamatsu T, Souma K, Oda T, HoshinoT, Sakura T, Ishizaki T, Shimizu H, Takizawa M, Yokohama A, Tsukamoto N, Handa H, Murakami H. PARP1 V762A polymorphism affects the prognosis of myelodysplasticsyndromes. Eur J Haematol. 2020 Jan 31. doi: 10.1111/ejh.13393.
  3. Matsumura I, Mitsui T, Tahara K, Shimizu H, Yanagisawa K, Ishizaki T, Koiso H, Takizawa M, Yokohama A, Saitoh T, Hirato J, Murakami H, Handa H, Tsukamoto N. IgG4-related Disease with a Cardiac Mass. Intern Med. 2020 Jan 17. doi: 10.2169/internalmedicine.4054-19.
  4. Kasamatsu T, Awata M, Ishihara R, Murakami Y, Gotoh N, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N,Saitoh T, Murakami H. PDCD1 and PDCD1LG1polymorphisms affect the susceptibility to multiple myeloma. Clin Exp Med. 20:51-62, 2020.
  5. Lee B, Phrasisombath K, Shinozaki H, Vangkonevilay P, Bouphavanh K, Prabouasone K, Sounthavong O, Tokita Y, Makino T, Matsui H, Saitoh T, Tozato F, Kama A, Watanabe H. Key factors affecting the integration of interprofessional education into human resources for health reform: a Lao People’s Democratic Republic case study. J Interprof Care. 33:356-360, 2019.
  6. Iriuchishima H, Maeshima A, Takahashi S, Ishizaki T, Yokohama A, Tsukamoto N, Saitoh T, Murakami H, Handa H. Activin A: a novel urinary biomarker of renalimpairment in multiple myeloma. Biosci Rep. 2019 May 31;39(5). doi: 10.1042/BSR20190206.
  7. Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Ann Hematol. 98:1703-1711, 2019.
  8. Handa H, Nishimoto N, Inoue M, Yokohama A, Tsukamoto N, Saitoh T, Murakami H. Human telomerase reverse transcriptase expression in a CD34-positive hematopoietic progenitor of myelodysplastic syndrome and acute myelogenous leukemia. Hematol Oncol. 37:520-522, 2019.
  9. Tahara K, Koiso H, Osaki YH, Sekigami T, Yokohama A, Saitoh T, Tsukamoto N, Murakami H, Abe M, Handa H. Malignancy-Associated Hypercalcemia Related with Receptor Activator of NF-κB Ligand (RANKL) Expression in T-Cell Acute Lymphoblastic Leukemia. Acta Haematol. 141:135-137, 2019.
  10. Takamatsu H, Yamashita T, Kurahashi S, Saitoh T, Kondo T, Maeda T, Nakazawa H, Murata M, Narita T, Kuroda J, Hashimoto H, Kawamura K, Miyamoto T, Honda S, Ichinohe T, Atsuta Y, Sunami K. Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 25:474-479, 2019.
  11. Mitsui T, Yokohama A, Koiso H, Saito A, Toyama K, Shimizu H, Ishizaki T, Irisawa H, Takizawa M, Saitoh T, Murayama K, Matsumoto M, Handa H, Hirato J,Kojima M, Murakami H, Tsukamoto N. Prognostic impact of trisomy 21 in follicular lymphoma. Br J Haematol. 184:570-577, 2019.
  12. Tsukamoto N, Yokohama A, Higuchi T, Mitsui T, Koiso H, Takizawa M, Shimizu H, Ishizaki T, Matsumoto M, Toyama K, Sakura T, Ogura H, Saitoh T, Ishida F, Murakami H, Tsushima Y, Handa H. Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy. Int J Hematol. 109:91-97, 2019.
  13. Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, ChoT, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma. Hematol Oncol. 36:792-800, 2018.
  14. Gotoh N, Saitoh T,Takahashi N, Kasamatsu T, Minato Y, Lobna A, Oda T, Hoshino T, Sakura T, Shimizu H, Takizawa M, Handa H, Yokohama A, Tsukamoto N, Murakami H. Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia. Int J Hematol. 108:246-253,2018.
  15. Nagashima T, Yokohama A, Nagai K, Kasamatsu T, Gotoh N, Iriuchishima H, Sekigami T, Saitoh T, Handa H, Tsukamoto N, Murakami H. Short-term administrationof recombinant human erythropoietin decreases B cell number in human peripheral blood. Transfus Apher Sci. 2018 Feb 2. pii: S1473-0502(18)30017-X.
  16. Yokohama A, Hashimoto Y, Takizawa M, Shimizu H, Miyazawa Y, Saitoh A, Toyama K, Ishizaki T, Mitsui T, Koiso H, Saitoh T, Murayama K, Matsumoto M, Sawamura M, Murakami H, Hirato J, Kojima M, Nojima Y, Handa H, Tsukamoto N. Clinical management and outcomes of completely resected stage I follicular lymphoma. J Clin Exp Hematop. 2018 Feb 8. doi: 10.3960/jslrt.17031.
  17. Kasamatsu T, Ino R, Takahashi N, Gotoh N, Minato Y, Takizawa M, Yokohama A, Handa H, Saitoh T, Tsukamoto N, Murakami H. PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. Br J Haematol. 2018 Jan 23. doi: 10.1111/bjh.15085.
  18. Kobayashi N, Mitsui T, Ogawa Y, Iriuchishima H, Takizawa M, Yokohama A, Saitoh T, Koiso H, Tsukamoto N, Murakami H, Nojima Y, Handa H. A Rare Case of Chronic Active Epstein-Barr Virus (EBV) Infection Accompanied by the Infiltration of EBV-infected CD8+ T Cells into the Muscle. J Pediatr Hematol Oncol. 2017 Dec 1. doi: 10.1097/MPH.0000000000001026.
  19. Makino T, Lee B, Matsui H, Tokita Y, Shinozaki H, Kanaizumi S, Abe Y, Saitoh T, Tozato F, Igarashi A, Sato M, Ohtake S, Tabuchi N, Inagaki M, Kama A, Watanabe H. Health science students’ attitudes towards healthcare teams: A comparison between two universities. J Interprof Care. 32:196-202、
  20. Handa H, Sasaki Y, Hattori H, Alkebsi L, Kasamatsu T, Saitoh T, Mitsui T, Yokohama A, Tsukamoto N, Matsumoto M, Murakami H. Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. Oncol Lett. 14:4372-4378, 2017.
  21. Takahashi N, Saitoh T, Gotoh N, Nitta Y, Alkebsi L, Kasamatsu T, Minato Y, Yokohama A, Tsukamoto N, Handa H, Murakami H. The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP. BMC Immunol. 2017 May 16;18(1):26. doi: 10.1186/s12865-017-0210-3.
  22. Kasamatsu T, Kimoto M, Takahashi N, Minato Y, Gotoh N, Takizawa M, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Saitoh T, Murakami H. IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma. Hematol Oncol. 2017 Aug 7. doi: 10.1002/hon.2469.
  23. Handa H, Kuroda Y, Kimura K, Masuda Y, Hattori H, Alkebsi L, Matsumoto M, Kasamatsu T, Kobayashi N, Tahara KI, Takizawa M, Koiso H, Ishizaki T, Shimizu H, Yokohama A, Tsukamoto N, Saito T, Murakami H. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14882.
  24. Tahara K, Takizawa M, Yamane A, Osaki Y, Ishizaki T, Mitsui T, Yokohama A, Saitoh T, Tsukamoto N, Matsumoto M, Murakami H, Nojima Y, Handa H. Overexpression B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response. Cancer Sci. 108:1556-1564, 2017.
  25. Shimizu H, Yokohama A, Ishizaki T, Hatsumi N, Takada S, Saitoh T, Sakura T, Nojima Y, Handa H. Clonal evolution detected with conventional cytogeneticanalysis is a potent prognostic factor in adult patients with relapsed AML. Hematol Oncol. 2017 Apr 4. doi: 10.1002/hon.2393.
  26. Norjmaa B, Saitoh T, Kasamatsu T, Minato Y, Murakami H. XRCC1 Arg194Trp and XRCC1 Arg399Gln Polymorphisms Affect Clinical Features and Prognosis of Myelodysplastic Syndromes The Kitakanto Medical Journal 67(1):93-94, 2017.
  27. Lee B, Shinozaki H, Bouphavanh K, Tokita Y, Makino T, Matsui H, Saitoh T, Tozato F, Watanabe H. A plan for embedding an interprofessional education initiative into an existing programme in a Southeast Asian university. J Interprof Care. 30:401-403, 2016.
  28. Kururi N, Tozato F, Lee B, Kazama H, Katsuyama S, Takahashi M, Abe Y, Matsui H, Tokita Y, Saitoh T, Kanaizumi S, Makino T, Shinozaki H, Yamaji T, Watanabe H. Professional identity acquisition process model in interprofessional education using structural equation modelling: 10-year initiative survey. J Interprof Care. 30:175-83, 2016.
  29. Alkebsi L, Handa H, Yokohama A, Saitoh T, Tsukamoto N, Murakami H. Chromosome 16q genes CDH1, CDH13 and ADAMTS18 are correlated and frequently methylated in human lymphoma. Oncol Lett. 12:3523-3530, 2016.
  30. Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Murakami H. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib. Hematol Oncol.35: 711-718, 2017.
  31. Kasamatsu T, Saitoh T, Minato Y, Shimizu H, Yokohama A, Tsukamoto N, Handa H, Sakura T, Murakami H. Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome. Eur J Haematol. 96: 245-251, 2016.
  32. Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K. Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902). Ann Hematol. 95:921-929, 2016.
  33. Mitsui T, Koiso H, Nakahashi H, Saitoh A, Shimizu H, Ishizaki T, Ogawa Y, Takizawa M, Yokohama A, Saitoh T, Jinbo T, Ogura H, Handa H, Sawamura M, Sakura T, Karasawa M, Murakami H, Nojima Y, Tsukamoto SF3B1 and IGHV gene mutationstatus predict poor prognosis in Japanese CLL patients. Int J Hematol. 103:219-226, 2016.
  34. Iriuchishima H, Ozaki S, Konishi J, Matsumoto M, Murayama K, Nakamura F,Yamamoto G, Handa H, Saitoh T, Nagura E, Shimizu K, Nojima Y, Murakami H. Primary plasma cell leukemia in the era of novel agents: A Multicenter Study of the Japanese Society of Myeloma. Acta Haematol135:113-121, 2016.
  35. Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Konishi J, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015 Sep 18;5:e349. doi: 10.1038/bcj.2015.79, 2015.
  36. Motohashi K, Fujisawa S, Onizuka M, Kako S, Sakaida E, Shono K, Tatara R, DokiN, Mori T, Sakura T, Aotsuka N, Fuji E, Tomita N, Kawai N, Saitoh T, Usuki K, Taguchi J, Watanabe R, Kobayashi S, Yano S, Kanamori H, Takahashi S, Okamoto S. Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 50:1476-1479, 2015.
  37. Kako S, Kanda Y, Kato J, Yamamoto W, Kato S, Onizuka M, Yokota A, Tatara R, Yokoyama H, Hagihara M, Usuki K, Gotoh M, Watanabe R, Kawai N, Saitoh T, Kanamori H, Takahashi S, Okamoto S. The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. Hematological Oncology DOI: 10.1002/hon.2276, 2015.
  38. Shimizu H, Saitoh T, Machida S, Kako S, Doki N, Mori T, Sakura T, Kanda Y, Kanamori H, Miyawaki S, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: Results of a matched-pair analysis Eur J Haematol 95(5) ejh.12516, 2015.
  39. Yano S, Mori T, Kanda Y, Kato J, Nakaseko C, Fujisawa S, Tomita N, Sakai R, Shono K, Saitoh T, Otsuka N, Kobayashi N, Saito T, Takahashi S, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. Bone Marrow Transplant. 50:1299-1305, 2015.
  40. Kasamatsu T, Saitoh T, Minato Y, Shimizu H, Yokohama A, Tsukamoto N, Handa H, Sakura T, Murakami H. Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome. Eur J Haematol.65:11-19, 2015.
  41. Tanaka M, Kanamori H, Matsumoto K, Tachibana T, Numata A, Ohashi K, Kobayashi T, Nakaseko C, Kanda Y, Yamazaki E, Fujisawa S, Ooi J, Sakura T, Aotsuka N, Onoda M, Machida S, Kato J, Usuki K, Watanabe R, Taguchi J, Yano S, Saito T, Takahashi S, Sakamaki H, Okamoto S; Kanto Study Group for Cell Therapy. Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. Bone Marrow Transplant. 50:727-733, 2015.
  42. Suto C, Murakami H, Kobayashi Y, Nagamine T, Saitoh T, Kasamatsu T, Ogawara H, Murakami M. High frequency of hepatitis B core and surface antibodies in hepatitis C virus-infected patients on the screening examination. Rinsho byori. 63:305-311, 2015.
  43. Norjmaa B, Saitoh T, Kasamatsu T, Minato Y, Murakami H, XRCC1 Arg194Trp and XRCC1 Arg399Gln polymorphisms affect clinical features and prognosis of myelodysplastic syndromes. The Kitakanto Medical Journal 65:11-19, 2015.
  44. Iriuchishima H, Saitoh T, Handa H, Isoda A, Matsumoto M, Sawamura M, Iwasaki A, Ushie C, Hattori H, Sasaki Y, Mitsui T, Yokohama A, Tsukamoto N, Murakami H, Nojima Y. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents. Eur J Haematol. 94:145-151, 2015.
  45. Watanabe S, Ide N, Ogawara H, Yokohama A, Mitsui T, Handa H, Koiso H, Tsukamoto N, Saitoh T, Murakami H. High percentage of regulatory T Cells before and after vitamin B12 treatment in patients with pernicious anemia. Acta Haematol.133:83-88, 2015.
  46. Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, Fujisawa S, Sakamaki H, Aotsuka N, Yokota A, Kanda Y, Sakura T, Nanya Y, Saitoh T, Kanamori H, Takahashi S, Okamoto S. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy. Biol Blood Marrow Transplant 10:1553-1559, 2014.
  47. Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, Mina R, Palumbo A, Shimizu K. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 132:211-219, 2014.
  48. Satoh Y, Ogawara H, Kawamura U, Shimoyama Y, Kusano M, Yokohama A, Saitoh T, Handa H, Tsukamoto N, Murakami H.Regulatory T cells percentage in peripheral blood before and after eradication of Helicobacter pylori Health 6:236-242, 2014.
  49. Hashimoto Y, Yokohama A, Saitoh A, Nakahashi H, Toyama K, Mitsui T, Koiso H, Saitoh T, Handa H, Uchiumi H, Jinbo T, Murayama K, Matsumoto M, Sawamura M, Karasawa M, Hirato J, Nojima Y, Kojima M, Tsukamoto N. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases. J Clin Exp Hematop. 53:197-205, 2013.
  50. Osaki Y, Yokohama A, Saito A, Tahara K, Yanagisawa K, Ogawa Y, Ishizaki T, Mitsui T, Koiso H, Takizawa M, Uchiumi H, Saitoh T, Handa H, Murakami H, Tsukamoto N Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? PLoS One 8:e81722, 2013.
  51. Alkebsi L, Handa H, Sasaki Y, Osaki Y, Yanagisawa K, Ogawa Y, Yokohama A, Hattori H, Koiso H, Saitoh T, Mitsui T, Tsukamoto N, Nojima Y, Murakami H. DNMT3B7 expression related to MENT expression and its promoter methylation in human lymphomas. Leuk Res. 37:1662-1667, 2013.
  52. Shimizu H, Saitoh T, Hatsumi N, Takada S, Handa H, Jimbo T, Sakura T, Miyawaki S, Nojima Y Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia. Leuk Res. 37:1477-1481, 2013.
  53. Kawamata N, Moreilhon C, Saitoh T, Karasawa M, Bernstein BK, Sato-Otsubo A, Ogawa S, Raynaud S, Koeffler HP Genetic differences between Asian and Caucasian chronic lymphocytic leukemia. Int J Oncol. 43:561-565, 2013.
  54. Mitsui T, Ishizaki T, Yokohama A, Koiso H, Uchiumi H, Saitoh T, Handa H , Hirato J, Karasawa M, Murakami H, Kojima M, Nojima Y, Tsukamoto N.Development of IgG4-related disease 10 years after chemotherapy for diffuse large B cell lymphoma and longstanding bronchial asthma. Int J Hematol. 98:122-128, 2013.
  55. Shimizu H, Handa H, Hatsumi N, Takada S, Saitoh T, Sakura T, Miyawaki S, Nojima Y. Distinctive disease subgroups according to differentiation stages in adult patients with T-cell acute lymphoblastic leukemia. Eur J Haematol. 90:301-307, 2013.
  56. Mitsui T, Mawatari M, Koiso H, Yokohama A, Uchiumi H, Saitoh T, Handa H, Hirato J, Murakami H, Kojima M, Nakamura S, Nakamura S, Nojima Y, Kanamori H, Tsukamoto N. Age-related epstein-barr virus-positive lymphoproliferative disorders of the orbit and maxillary sinus J Clin Exp Hematop. 52:205-209, 2012.
  57. Yokohama A, Saitoh A, Nakahashi H, Mitsui T, Koiso H, Kim Y, Uchiumi H, Saitoh T, Handa H, Jimbo T, Murayama K, Sakura T, Murakami H, Karasawa M, Nojima Y, Tsukamoto N. TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients. Int J Hematol. 95, 77-85, 2012.
  58. Koiso H, Yokohama A, Mitsui T, Saitoh T, Handa H, Murakami H, Hirato J, Kojima M, Nojima Y, Tsukamoto N.Follicular lymphoma presenting with marked splenomegaly: report of three cases Acta Haematol.12, 47-52, 2012.
  59. Saito A, Yokohama A, Osaki Y, Ogawa Y, Nakahashi H, Toyama K, Mitsui T, Hashimoto Y, Koiso H, Uchiumi H, Saitoh T, Handa H, Sawamura M, Karasawa M, Murakami H, Tsukamoto N, Nojima Y. Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia. Eur J Haematol.88, 340-349, 2012.
  60. Shimizu H, Saitoh T, Hatsumi N, Takada S, Yokohama A, Handa H, Jimbo T, Sakura T, Tsukamoto N, Murakami H, Miyawaki S, Nojima Y. Clinical significance of granulocytic sarcoma in adult patients with acute myeloid leukemia. Cancer Sci.103 1513-1517, 2012.
  61. Shimizu H, Saitoh T, Tanaka M, Mori T, Sakura T, Kawai N, Kanda Y, Nakaseko C, Yano S,Fujita H, Fujisawa S, Miyawaki S, Kanamori H, Okamoto S. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia 26 2469-2473, 2012.
  62. Yokohama A, Saitoh A, Nakahashi H, Mitsui T, Koiso H, Kim Y, Uchiumi H, Saitoh T, Handa H, Jimbo T, Murayama K, Sakura T, Murakami H, Karasawa M, Nojima Y,Tsukamoto N. TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients. Int J Hematol. 95:77-85, 2012.
  63. Saitoh T, Kasamatsu T, Inoue M, Mitsui T, Koiso H, Yokohama A, Handa H, Matsushima T, Tsukamoto N, Karasawa M, Ogawara H, Nojima Y, Murakami H. Interleukin-10 gene polymorphism reflects the severity of chronic immune thrombocytopenia in Japanese patients. Int J Lab Hemtol. 33:526-32, 2011.
  64. Saitoh T, Tsukamoto N, Koiso H, Mitsui T, Yokohama A, Handa H, Karasawa M, Ogawara H, Nojima Y, Murakami H. Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia. Eur J Haematol. 87:253-258, 2011.
  65. Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 126:114-118, 2011.
  66. Yuzuriha A, Saitoh T, Koiso H, Mitsui T, Uchiumi H, Yokohama A, Handa H, Kojima M, Tsukamoto N, Karaswa M, Murakami H, Nojima Y. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol.126:147-50, 2011.
  67. Shimizu H, Saitoh T, Koya H, Yuzuriha A, Hoshino T, Hatsumi N, Takada S, Nagaki T, Nojima Y, Sakura T. Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplantlymphoproliferative disorder. Int J Hematol. 94:495-8, 2011.
  68. Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T, Handa H, Murakami H, Nojima Y, Tsukamoto N. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes. Intern Med. 50:2557-61, 2011.
  69. Matsumoto K, Yokohama A, Yuzuriha A, Toyama K, Mitsui T, Hashimoto Y, Koiso H, Saitoh T, Uchiumi H, Handa H, Karasawa M, Murakami H, Matsu Hi, Suzuki K, Tsukamoto N, and Yoshihisa Nojima Sunitinib Induced Immune Thrombocytopenia Kitakanto Med J. 61:175-177, 2011.
  70. Nakaseko C, Ozawa S, Sakaida E, Sakai M, Kanda Y, Oshima K, Kurokawa M, Takahashi S, Ooi J, Shimizu T, Yokota A, Yoshiba F, Fujimaki K, Kanamori H, Sakai R, Saitoh T, Sakura T, Maruta A, Sakamaki H, Okamoto S. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol. 93:375-82, 2011.
  71. Tsukamoto N, Handa H, Yokohama A, Mitsui T, Saitoh T, Koiso H, Uchiumi H, Hoshino T, Karasawa M, Murakami H, Kojima M, Nojima Y. Long-term follow-up of EBV-positive lymphoproliferative disorders in a patient with systemic lupus erythematosus. Med Mol Morphol. 44:237-41, 2011.
  72. Handa H, Matsushima T, Nishimoto N, Inoue M, Saitoh T, Yokohama A, Tsukamoto N, Mitsui T, Nakahashi H, Toyama K, Karasawa M, Ogawara H, Nojima Y, Murakami H. Flow cytometric detection of human telomerase reverse transcriptase (hTERT) expression in a subpopulation of bone marrow cells. Leuk Res. 34:177-183, 2010.
  73. Nakahashi H, Tsukamoto N, Hashimoto Y, Koiso H, Yokohama A, Saitoh T, Uchiumi H, Handa H, Murakami H, Nojima Y, Karasawa M. Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders. Cancer Sci. 100:671-677, 2009.
  74. Hashimoto Y, Tsukamoto N, Nakahashi H, Yokohama A, Saitoh T, Handa H, Matsushima T, Murakami H, Nojima Y, Karasawa M. Hairy cell leukemia-related disorders consistently show low CD27 expression. Pathol Oncol Res. 15:615-621, 2009.
  75. Toyama K, Karasawa M, Yamane A, Koiso H, Yokohama A, Uchiumi H, Saitoh T, Handa H, Sato K, Takagi H, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N. Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome. Int J Hematol. 89:517-522, 2009.
  76. Nakahashi H, Tsukamoto N, Yamane A, Saitoh T, Uchiumi H, Handa H, Karasawa M, Murakami H, Kojima M, Nojima Y.Autologous peripheral blood stem cell transplantation to treat CHOP-refractory aggressive subcutaneous panniculitis-like T cell lymphoma. Acta Haematol. 121:239-242, 2009.
  77. Yamane A, Tsukamoto N, Saitoh T, Uchiumi H, Handa H, Karasawa M, Nojima Y, Murakami H. Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney. Intern Med. 48:1691-1694, 2009.
  78. Saitoh T, Matsushima T, Kaneko Y, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H. T cell large granular lymphocyte (LGL) leukemia associated with Behcet’s disease: high expression of sFasL and IL-18 of CD8 LGL. Ann Hematol. 87:585-586, 2008.
  79. Saitoh T, Matsushima T, Saito Y, Yamane A, Yokohoma A, Irisawa H, Handa H, Tsukamoto N, Karasawa M, Kojima M, Nojima Y, Murakami H. Hodgkin lymphoma presenting with various immunologic abnormalities, including autoimmune hepatitis, Hashimoto’s thyroiditis, autoimmune hemolytic anemia, and immune thrombocytopenia. Clin Lymphoma Myeloma. 8:62-64, 2008.
  80. Akagi T, Saitoh T, O’Kelly J, Akira S, Gombart AF, Koeffler HP. Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP [beta]-deficient hematopoietic cells Blood. 111:2999-3004, 2008.
  81. Saitoh T, Matsushima T, Irisawa H, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H. Successful treatment with voriconazole of Aspergillus meningitis in a patient with acute myeloid leukemia. Ann Hematol. 86:697-698, 2007.
  82. Saitoh T, Matsushima T, Yamane A, Sakuraya M, Irisawa H, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H. Hodgkin Lymphoma Accompanied by Aplastic Anemia and Polyclonal Expansion of Large Granular Lymphocytes. Acta Haematol. 117:238-241, 2007.
  83. Saitoh T, Matsushima T, Matsuo A, Yokohama A, Irisawa H, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H. Small-bowel perforation accompanied by Aspergillus endocarditis in a patient with angioimmunoblastic T-cell lymphoma. Ann Hematol. 86:71-73, 2007.
  84. Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, Saitoh T, Handa H, Endo K, Murakami H. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. 110:652-659, 2007.
  85. Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, Handa H, Matsushima T, Sawamura M, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol. 139:64-69, 2007.
  86. Uchiumi H, Matsushima T, Yamane A, Doki N, Irisawa H, Saitoh T, Sakura T, Jimbo T, Handa H, Tsukamoto N, Karasawa M, Miyawaki S, Murakami H, Nojima Y. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol. 86:137-42, 2007.
  87. Hoshino T, Matsushima T, Saitoh Y, Yamane A, Takizawa M, Irisawa H, Saitoh T, Handa H, Tsukamoto N, Karasawa M, Murakami H, Nojima Y. Sacroiliitis as an initial manifestation of acute myelogenous leukemia. Int J Hematol. 84:421-424, 2006.
  88. Saitoh T, Matsushima T, Iriuchishima H, Yamane A, Irisawa H, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H. Presentation of extramedullary Philadelphia chromosome-positive biphenotypic acute leukemia as testicular mass: Response to imatinib-combined chemotherapy. Leuk Lymphoma. 47:2667-2669, 2006.
  89. Saitoh T, Matsushima T, Toyama K, Yamane A, Irisawa H, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H. Copper deficiency pancytopenia with infectious complications after hemolytic anemia. Ann Hematol. 85:881-882, 2006.
  90. Ikezoe T, Yang Y, Saitoh T, Heber D, McKenna R, Taguchi H, Koeffler HP. PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells. Int J Oncol. 29:453-461, 2006.
  91. Mitsui T, Tsukamoto N, Kanegane H, Agematsu K, Sekigami T, Irisawa H, Saitoh T, Uchiumi H, Handa H, Matsushima T, Karasawa M, Murakami H, Miyawaki T, Nojima Y. X-linked agammaglobulinemia diagnosed in adulthood: a case report. Int J Hematol. 84:154-157, 2006.
  92. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP, Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol.33:53-61, 2005.
  93. Kawabata H, Fleming RE, Gui D, Moon SY, Saitoh T, O’Kelly J, Umehara Y, Wano Y, Said J.W., Koeffler H.P., Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood. 105:376-381, 2005.
  94. Yamane A, Shinmura K, Sunaga N, Saitoh T, Yamaguchi S, Shinmura Y, Yoshimura K, Murakami H, Nojima Y, Kohno T, Yokota J. Suppressive activities of OGG1 and MYH proteins against G:C to T:A mutations caused by 8-hydroxyguanine but not by benzo[a]pyrene diol epoxide in human cells in vivo. Carcinogenesis. 24:1031-1037, 2003.
  95. Hatsumi N, Saitoh T, Yokohama A, Uchiumi H, Matsushima T, Tsukamoto N, Nojima Y, Karasawa M, Handa H, Ogawara H, Murakami H. Ribosome-lamella complex of leukemic cells in a patient with aggressive NK cell leukemia. Ultrastruct Pathol.26:415-417, 2002.
  96. Vegesna V, O’Kelly J, Uskokovic M, Said J, Lemp N, Saitoh T, Ikezoe T, Binderu L, Koeffler H.P. Vitamin D3 analogs stimulate hair growth in nude mice. Endocrinology. 143:4389-4396, 2002.
  97. Yamaguchi S, Shinmura K, Saitoh T, Takenoshita S, Kuwano H, Yokota J. A single nucleotide polymorphism at the splice donor site of the human MYH base excision repair genes results in reduced translation efficiency of its transcripts. Genes Cells. 7:461-474, 2002.
  98. Matsushima T, Saitoh T, Karasawa M, Takizawa M, Miyawaki S, Nojima Y, Murakami H. Effect of cytokines on growth and differentiation of leukaemic cells with translocation t(6;9)(p23;q34).Br J Haematol. 115:812-816, 2001.
  99. Murakami H, Hayashi K, Hatsumi N, Saitoh T, Yokohama A, Matsushima T, Tsukamoto N, Morita K, Karasawa M, Ogawara H, Sawamura M, Nojima Y. Risk factors for early death in patients undergoing treatment for multiple myeloma. Ann Hematol. 80:452-455, 2001.
  100. Saitoh T, Shinmura K, Yamaguchi S, Tani M, Seki S, Murakami H, Nojima Y, Yokota J. Enhancement of OGG1 protein AP lyase activity by increase of APEX protein. Mutat. Res. 486:31-40, 2001.
  101. Sunaga N, Kohno T, Shinmura K, Saitoh T, Matsuda T, Saito R, Yokota J. OGG1 Protein Suppresses G:C to T:A Mutation in a Shuttle Vector Containing 8-Hydroxyguanine in Human Cells. Carcinogenesis. 22:1355-1362, 2001.
  102. Shinmura K, Yamaguchi S, Saitoh T, Kohno T, Yokota J. Somatic mutations and single nucleotide polymorphisms of base excision repair genes involved in the repair of 8-hydroxyguanine in damaged DNA. Cancer Lett. 166:65-69, 2001.
  103. Shinmura K, Yamaguchi S, Saitoh T, Takeuchi-Sasaki M, Kim S R, Nohmi T, Yokota J. Adenine excisional repair function of MYH protein on the adenine:8-hydroxyguanine base pair in double-stranded DNA. Nucl. Acids. Res. 28: 4912-4918, 2000.
  104. Takada S, Hatsumi N, Saitoh T, Matsushima T, Sakura T, Tamura J, Karasawa M, Miyawaki S. Two cases of chronic graft-versus-host disease with elevated levels of soluble Fas ligand in serum. Am. J. Hematol. 64:133-136, 2000.
  105. Murakami H Takada S, Hatsumi N, Yokohama A, Saitoh T, Uchiumi H, Maehara T, Matsushim T, Tsukamoto N, Morita K, Tamura J, Sawamura M, Karasawa M. Multiple myeloma presenting high fever and high serum levels of lactic dehydrogenase, CRP, and interleukin-6. Am J Hematol. 64:76-77, 2000.
  106. Saitoh T, Karasawa M, Sakuraya M, Nakamura N, Tohma J, Shirakawa K, Matsushima T, Tsukamoto N, Nojima Y, Murakami H. Improvement of extrathymic T cell type of large granular lymphocyte (LGL) leukemia by cyclosporin A: the serum level of Fas ligand is a marker of LGL leukemia activity. Eur. J. Haematol. 65:272-275, 2000.
  107. Saitoh T, Murakami H, Hatsumi N, Matsushima T, Naruse, T. Detection of VP-16-treated HL-60 cell apoptosis by TUNEL electron microscopy. Ultrastruct. Pathol. 24:99-103, 2000.
  108. Kawada E, Shinonome S, Saitoh T, Tamura J, Karasawa M, Sawamura M, Murakami H. Primary nonsecretory plasma cell leukemia: a rare variant of multiple myeloma. Ann Hematol. 78:25-27, 1999.
  109. Tamura J, Kubota K, Murakami H, Sawamura M, Matsushima T, Tamura T, Saitoh T, Kurabayshi H, Naruse T. Immunomodulation by vitamin B12: augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment. Clin. Exp. Immunol. 116:28-32, 1999.
  110. Yamamoto T, Tamura J, Orima S, Saitoh T, Sakuraya M, Maehara T, Shirota A, Maezawa A, Nojima Y, Naruse T Rhabdomyosarcoma in a patient with mosaic Klinefelter syndrome and transformation of immature teratoma. J. Int. Med. Res. 27:196-200, 1999.
  111. Takada S, ItoK, Sakura T, Hatsumi N, Sato M, Saitoh T, Shiozaki H. Matsushima T, Miyawaki S. Three AML patients with existing or pre-existing intracerebral granulocytic sarcomas who were successfully treated with allogeneic bone marrow transplantations. Bone Marrow Transplant. 23:731-734, 1999.
  112. Murakami H, Hatsumi N, Saitoh T, Mitsui T, Matsushima T, Tsukamoto N, Morita K, Tamura J, Karasawa M. Electron microscopical analysis of myeloperoxidase of leukemic cells in CD7+ stem cell leukemia/lymphoma. Eur J Haematol. 62:350-351, 1999.
  113. Murakami H, Kawada T, Saitoh T, Uchiumi H, Moridaira K, Matsushima T, Tsukamoto N, Tamura J, Morita K, Sawamura M, Karasawa M, Miyawaki S, Shinonome S, Shimano A. Staging system for multiple myeloma based on the morphology of myeloma cells. Eur J. Haematol., 62:63-67, 1999.
  114. Saitoh T, Murakami H, Uchiumi H, Moridaira K, Maehara T, Matsushima T, Tsukamoto N, Tamura J, Karasawa M, Naruse T, Tsuchiya J. Myelodysplastic syndromes with nephrotic syndrome. Am J. Hematol. 60:200-204, 1999.
  115. Moridaira K , Tamura J, Saitoh T, Kanai M, Itoh K, Uchiyama T, Takeuchi T, Sato S, Matsushima T, Murakami H, Naruse T, Tsuchiya J. Non-Hodgkin’s lymphoma following acute myeloid leukemia in complete remission. Acta Haematol. 100:97-98, 1998.
  116. Sato M, Matsushima T, Takada S, Hatsumi N, Kim K, Sakuraya M, Saitoh T, Tamura J, Karasawa M, Murakami H, Naruse T. Fulminant, CMV-associated, haemophagocytic syndrome following unrelated bone marrow transplantation. Bone Marrow Transplant. 22:1219-1222, 1998.
  117. Sakura T, Murakami H, Saitoh T, Naruse T,Tsuchiya J. Ultrastructural abnormalities of bone marrow erythroblast in refractory anemia. Ultrastruct Pathol, 22:173-180, 1998.
  118. Saitoh T, Murakami H, Hayashi K, Matsushima T, Tamura J, Karasawa M, NaruseT, Tsuchiya J. Coincidental occurrence of pernicious anemia and mycosis fungoides in two elderly males. Am. J. Hematol, 58:127-129, 1998.
  119. Maeshima A, Murakami H, Sadakata H, Saitoh T, Matsushima T, Tamura J, Karasawa M, Naruse T. Eosinophilic gastroenteritis presenting with acute pancreatitis. J of Med, 28:265-272, 1997.
  120. Murakami H, Ogawara H, Morita K, Saitoh T, Matsushima T, Tamura J, Sawamura M, Karasawa M, Miyawaki S, Shimano S, Satoh S, Tsuchiya J. Serum beta-2-microglobulin in patients with multiple myeloma treated with alpha interferon. J of Med., 28: 311-318, 1997.
  121. Murakami H, Irisawa H, Saitoh T, Matsushima T, Tamura J, Sawamura M, Karasawa M, Hosomura M, Kojima M Immunological abnormalities in splenic marginal zone cell lymphoma. Am. J. Hematol., 56:173-178, 1997.